This article is part of MPR‘s coverage of the American Academy of Allergy, Asthma & Immunology annual meeting, taking place in San Francisco, California. Our staff will report on medical research related to asthma, allergy, and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI 2019.
SAN FRANCISCO — Treatment with the humanized anti-interleukin-5 monoclonal antibody reslizumab has been associated with clinically meaningful improvements in asthma control and quality of life (QoL), according to the results of 2 clinical trials presented at the American Academy of Allergy, Asthma & Immunology 2019 Annual Meeting in San Francisco, held February 22-25.
Investigators sought to examine trends during 52 weeks of treatment with reslizumab vs placebo with respect to improvements in QoL and asthma control based on the minimal important difference in the Asthma Control Questionnaire (ACQ) and asthma-related quality of life (AQLQ) scores. All data were pooled from two 52-week studies of intravenous reslizumab (3mg/kg every 4 weeks) vs placebo. The ACQ-7 was assessed every 4 weeks and the AQLQ was assessed every 16 weeks from baseline. All reported response rates reflect the percentages of patients who attained minimal important difference (ie, 0.5-point improvement) in each of the scores at each visit.
A total of 953 participants were evaluated, with 477 treated with reslizumab and 476 receiving placebo. Overall, approximately 60% of patients treated with reslizumab and approximately 50% of patients given placebo were ACQ-7 responders at week 4 (P=.001). The mean treatment difference was –0.219 (P<.0001). Maximum ACQ-7 response rates were reported at week 32, occurring in approximately 77% of patients treated with reslizumab and approximately 67% of patients given placebo (P=.001). The mean treatment difference was –0.228 (P<.001).
Regarding AQLQ scores, approximately 66% patients treated with of reslizumab and approximately 57% of patients given placebo were responders at week 16, resulting in a mean treatment difference of 0.210 (P=.0019). Maximum AQLQ response rates were reported at week 52, occurring in approximately 73% of patients treated with reslizumab and approximately 63% of patients given placebo, resulting in a mean treatment difference of 0.317 (P<.0001).
The investigators concluded that although ACQ responses plateaued after 32 weeks, the AQLQ response rates continued to increase during the entire treatment period. This suggests that there may be more QoL benefits gained from anti-interleukin-5 treatment throughout the initial year of therapy.
Visit Monthly Prescribing Reference‘s conference section for continuous coverage of AAAAI 2019.
Hickey L, Carr W, Garin M. Clinically meaningful improvements in asthma control questionnaire (ACQ) scores occur early, while asthma-related quality of life (AQLQ) scores continue to improve over 52 weeks, among patients with eosinophilic asthma receiving IV reslizumab. Presented at: American Academy of Allergy, Asthma & Immunology Annual Meeting; February 22-25, 2019; San Francisco, CA. Abstract 291.